Skip to main content

Table 1 Baseline characteristics

From: Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy

Characteristics No. of patients (%)
Age (yr)
Median 64.57
Range 39.2–87.1
Histological type
HGSC 120 (90.9%)
Endometrioid 1 (0.8%)
Undifferentiated 2 (1.5%)
Not specified 9 (6.8%)
FIGO stage
IIIC 90 (68.2%)
IV 41 (31.1%)
Not specified 1 (0.8%)
Regimen of NAC
Taxane+carboplatin 113 (85.6%)
Other 16 (12.1%)
Not specified 3 (2.3%)
Debulking surgery
Yes 103 (78%)
No 29 (22%)
ECOG score
0–1 93 (70.4%)
2–3 25 (18.9%)
4 2 (1.5%)
Not specified 12 (9.1%)
NLR
≤ 3 37 (28%)
> 3 95 (72%)
CRS
CRS1/2 50 (68.5%)
CRS3 23 (31.5%)
Debulking
Optimal 60 (58.2%)
Suboptimal 33 (32%)
Not specified 10 (9.7%)
BRCA testing
Yes 46 (34.8%)
No 85 (64.4%)
Not specified 1 (0.8%)
BRCA mutation
Yes 11 (8.3%)
No 36 (27.3%)
Unknown 85 (64.4%)
Bevacizumab treatment
Yes 42 (31.8%)
No 74 (56.1%)
Not specified 16 (12.1%)